Stock LIFE ATYR PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings aTyr Pharma, Inc.

Equities

LIFE

US0021202025

Market Closed - Nasdaq
Other stock markets
 02:00:01 04/05/2024 am IST 		5-day change 1st Jan Change
1.61 USD +0.62% Intraday chart for aTyr Pharma, Inc. +2.55% +14.18%
02/05 ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
02/05 Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000 MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analyst opinion has improved significantly over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
ATYR PHARMA, INC. Stock aTyr Pharma, Inc.
+14.18% 109M -
MODERNA, INC. Stock Moderna, Inc.
+25.69% 47.9B
B-
LONZA GROUP AG Stock Lonza Group AG
+46.90% 41.42B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.7B
B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.92B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 25.55B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.27B
B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 12.15B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.14B
C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.99B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. LIFE Stock
  4. Ratings aTyr Pharma, Inc.